Singular Genomics Systems (OMIC): Rentabilitas operasi

Singular Genomics Systems - logo grafis emiten OMIC

Singular Genomics Systems (OMIC) generates revenue through the sale of benchtop analyzers and accompanying reagents for DNA diagnostics. Operating profit margins on GURU.Markets show a local peak, where the -3488.50 mark characterizes this parameter. The stability of operating profitability is supported by the diversification of optics suppliers. However, small-batch production of instruments limits the leverage effect, maintaining a high unit cost for the equipment.

OMIC: Rentabilitas kegiatan operasi singulargenomics.com 04.07.2022 - 01.03.2025

OMIC (Singular Genomics): rincian analitis lan laporan miturut indikator

Pambiji fundamental perusahaan:OMIC, Singular Genomics Corp
Barang utama singulargenomics.com

To identify a fundamental support level for the Singular Genomics Systems (OMIC) business, it is essential to evaluate the effectiveness of its competition with monopolists via the operating profit margin. This chart measures the share of profit from core operations relative to total revenue, reflecting the ability of the open-architecture sequencing systems to generate cash flow before taxes and interest, which determines the long-term sustainability of the asset.

Analisis pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Sangamo Therapeutics Inc. - Margin operasi|NAUT - Margin operasi|MGX: Margin operasi|Margin dodolan operasi Precision BioSciences, Inc.|GBIO (Generation Bio) - Margin operasi|Boundless Bio Inc. (BOLD) - Rentabilitas kegiatan operasi|Margin dodolan operasi XCUR (exicuretx.com)|Imunon Inc - Rentabilitas dodolan miturut bathi operasi|Margin operasi PHIO (Phio Pharmaceuticals Corp)|Tingkat bathi operasi MBIO|RNAZ - Rentabilitas operasi|Tingkat bathi operasi BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Rentabilitas operasi|Bluebird Bio - Tingkat bathi operasi|IPA (ImmunoPrecise Antibodies Ltd) - Margin operasi|Rentabilitas dodolan operasi Omega Therapeutics, Inc. OMGA|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi